Novo Nordisk A/S (CPH: NOVO.B)
Denmark
· Delayed Price · Currency is DKK
603.70
-4.00 (-0.66%)
Jan 30, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 71.31B DKK in the quarter ending September 30, 2024, with 21.42% growth. This brings the company's revenue in the last twelve months to 270.58B, up 26.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
270.58B
Revenue Growth
+26.15%
P/S Ratio
9.95
Revenue / Employee
3.76M
Employees
64,319
Market Cap
2,680.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coloplast | 27.03B |
Genmab | 19.84B |
Demant | 22.84B |
Zealand Pharma | 76.87M |
H. Lundbeck | 21.44B |
Ambu A/S | 5.39B |
ALK-Abelló | 5.38B |
GN Store Nord | 18.04B |
Novo Nordisk News
- 2 hours ago - Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - Accesswire
- 5 hours ago - Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NVO - Accesswire
- 6 hours ago - Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More - Accesswire
- 7 hours ago - NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PRNewsWire
- 9 hours ago - Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO - Accesswire
- 9 hours ago - Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman - GlobeNewsWire
- 10 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit – NVO - GlobeNewsWire
- 11 hours ago - Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders - Accesswire